G
Genomics
United kingdom-based genomic data company
About Genomics
Genomics plc is an innovative health business dedicated to transforming health, healthcare, and drug discovery through the power of genomics. The company operates in the genomics market, providing solutions that empower patients, practitioners, pharmaceutical companies, healthcare providers, and payers to make genomically powered decisions for longer, healthier lives. Genomics plc's business model focuses on leveraging genomic data to drive transformational insights into human biology and disease, thereby improving the quality of healthcare delivery and drug discovery processes. The company generates revenue through partnerships with healthcare systems, pharmaceutical companies, and other stakeholders in the healthcare ecosystem. By integrating genomic data into clinical practice and research, Genomics plc aims to enhance personalized medicine and optimize treatment outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Oxford, United Kingdom
- Employees
- 187
- Open positions
- 8
- Dealroom signal
- 75.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Analytics, Biotechnology, Drug Development, DNA, Genetics and genomics, Spinout, Genome Engineering, Tech for Biotech and Pharma
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing, SaaS
Latest news
Press, funding announcements and product moves mentioning Genomics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2024 | $46M | $185M | Foresite Capital · F-Prime · Infinity Investment Partners | ↗ |
| LATE VCOther financing | Mar 2021 | $30M | $120M | Oxford Science Enterprises · Lansdowne Partners · Foresite Capital · F-Prime | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Genomics is 14K monthly website visits, up 27.3% over the last three months. Genomics's team declined 8.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Woodford Investment Management
Lansdowne Partners
Invesco
Vertex Pharmaceuticals
IP Group
Tanarra
Invesco Perpetual
Oxford Science Enterprises
Foresite Capital
F-Prime
Series B and later1 investor entered at this stage
- IPInfinity Investment Partners
Other known investors2 additional known investors
Oxford University Innovation
University of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.